Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Payables (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Payables for 13 consecutive years, with $47.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 2.61% year-over-year to $47.5 million, compared with a TTM value of $47.5 million through Sep 2025, down 2.61%, and an annual FY2024 reading of $44.7 million, down 9.79% over the prior year.
  • Payables was $47.5 million for Q3 2025 at Tandem Diabetes Care, down from $55.8 million in the prior quarter.
  • Across five years, Payables topped out at $61.5 million in Q3 2022 and bottomed at $27.0 million in Q3 2021.
  • Average Payables over 5 years is $46.6 million, with a median of $48.1 million recorded in 2024.
  • The sharpest move saw Payables surged 128.12% in 2022, then fell 25.01% in 2023.
  • Year by year, Payables stood at $28.0 million in 2021, then soared by 98.81% to $55.7 million in 2022, then dropped by 11.02% to $49.6 million in 2023, then dropped by 9.79% to $44.7 million in 2024, then grew by 6.15% to $47.5 million in 2025.
  • Business Quant data shows Payables for TNDM at $47.5 million in Q3 2025, $55.8 million in Q2 2025, and $59.8 million in Q1 2025.